Treatment of ST-elevation myocardial infarction

Area of Science:

• Cardiology
• Internal Medicine
• Emergency Medicine

Background:

• ST-segment elevation myocardial infarction (STEMI) requires prompt treatment to improve prognosis.
• Restoring blood flow in the infarct artery is a critical initial step.
• Primary percutaneous coronary intervention (PCI) is a key reperfusion strategy.

Purpose of the Study:

• To review the optimal initial management strategies for STEMI.
• To compare the effectiveness of different reperfusion therapies and adjunctive treatments.
• To discuss secondary prevention and device therapy in STEMI patients.

Main Methods:

• Review of current guidelines and clinical trial evidence for STEMI management.
• Comparison of primary PCI versus fibrinolytic therapy.
• Evaluation of adjunctive pharmacotherapies, including antiplatelets and anticoagulants.
• Discussion of evidence for beta-blockers, ACE inhibitors, statins, and glucose control in diabetic patients.
• Consideration of implantable cardioverter-defibrillator (ICD) therapy in high-risk patients.

Main Results:

• Primary PCI demonstrates superior short- and long-term survival compared to fibrinolysis in STEMI.
• Drug-eluting stents may reduce restenosis, but mortality benefits are less certain.
• Glycoprotein IIb/IIIa inhibitors and bivalirudin can reduce periprocedural complications, with bivalirudin offering less bleeding risk.
• Beta-blockers, ACE inhibitors, and statins are recommended for all STEMI patients, with caution for beta-blockers in shock-risk patients.
• Optimal glucose control is essential for diabetic STEMI patients.
• ICD implantation is recommended for high-risk patients (low ejection fraction) after 30 days, but its benefit post-primary PCI without heart failure is unclear.

Conclusions:

• Primary PCI is the preferred reperfusion strategy for STEMI.
• Comprehensive medical therapy, including guideline-directed medications, is essential.
• Careful patient selection is necessary for device therapies like ICDs.